Robert Morris
Robert Morris's Latest Posts
BST Trade Alert – January 22, 2016
Recommendation: Buy ImmunoGen (NASDAQ: $IMGN) up to $11.00 per share. About the Company: ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADC) that are designed to fight cancer. They developed the ADC technology to enable the creation of better therapies for people with cancer. The concept of an ADC is simple: […]
BST Position Update – January 8, 2016
. . . . CoLucid Pharmaceuticals (NASDAQ: $CLCD) – Hold CLCD reached a high of $8.95 this week. That pushed the gains on this biotech stock to 90% from our buy price. The company is working on a new treatment for migraine headaches. They are working on the first of two Phase 3 clinical trials. […]
BST Trade Alert – December 18, 2015
Recommendation: Buy Insmed (NASDAQ: $INSM) up to $20.00 per share. About the Company: Insmed is a biopharmaceutical company focused on developing drugs to treat rare diseases. They are developing novel, targeted therapies to help service the unmet needs of these patients. About the Drug: Insmed currently has 1 drug, ARIKAYCE, in clinical testing. ARIKAYCE is […]
BST Position Update – December 3, 2015
. . . . CoLucid Pharmaceuticals (NASD: $CLCD) – Hold CoLucid Pharmaceuticals is our latest trade. And it’s good one! CLCD is up 8% today and 45% since we recommended buying it to $6.81. Investors are clearly warming up to the idea that they could have a blockbuster drug on their hands if they can […]
BST Trade Alert – November 20, 2015
Recommendation: Buy CoLucid Pharmaceuticals (NASDAQ: $CLCD) up to $5.00 per share. About the Company: CoLucid Pharmaceuticals is a clinical-stage pharmaceutical company. They are developing an innovative and proprietary small molecule for the treatment of migraine headaches. The company was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in […]
BST Position Update – November 13, 2015
. . . . Xencor Inc. (NASDAQ: $XNCR) – Hold Xencor Inc. has announced a research and licensing agreement has been struck with Amgen Inc. $AMGN, for the development and commercialization of novel treatments targeting the areas of cancer immunotherapy and inflammation. Shares of the stock rose 15% after this announcement was made. The company […]
BST Position Update – November 6, 2015
. . . . Threshold Pharmaceuticals (NASD: $THLD) – Buy Threshold Pharmaceuticals announced last month that they have received two U.S. patents for Tarloxotinib Bromide, a promising treatment for non-small cell lung cancer and patients with squamous cell cancers of the head and neck or skin. The drug is currently in a Phase 2 clinical […]
BST Position Update – October 30, 2015
. . . . Verastem (NASD: $VSTM) – Sell Verastem stock has tanked after announcing they have halted their drug study. The company has stopped a mid-stage study of VS-6063, Verastem’s leading mesothelioma cancer treatment candidate, after studies showed the treatment was not effective enough to warrant any further studies. Let’s cut our losses and […]
BST Position Update – October 23, 2015
. . . . Xenor (NASD: $XNCR) – Hold Xenor has just initiated Phase 2 clinical trial of a biological candidate using XmAb Cytotoxix Fc domain for the treatment of asthma and allergic diseases. Xenor has narrowed their current quarter loss from 21 cents a share to 17 cents a share. We are seeing solid […]
BST Position Update – October 16, 2015
. . . . Anthera Pharmacuticals (NASDAQ: $ANTH) – Buy Anthera currently has three drugs that are in the clinical stage of research, SOLUTION, Chablis-SC, and Bright-SC. Anthera recently announced that they have regained worldwide rights to the drug, Blisibimod, which is being tested in the Chablis-SC study, after ending a partnership with Zanyaku, a […]
